📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Stallion India Allots 3.67 Cr Equity Shares via Rights Issue at Rs 99 Per Share
Stallion India Fluorochemicals has successfully completed the allotment of 3,67,60,483 equity shares through a Rights Issue. The shares were issued at a price of Rs 99 per share (including premium) in a ratio of 19:41 to eligible shareholders. This allotment increases the company's total paid-up equity capital to Rs 116.09 crore, comprising 11,60,85,737 shares. The company also issued a correction to clarify that the face value of the shares is Rs 10, not Re 1 as previously stated.
Key Highlights
Allotment of 3,67,60,483 fully paid-up equity shares at an issue price of Rs 99 per share
Rights issue ratio maintained at 19 shares for every 41 shares held as of February 11, 2026
Post-allotment paid-up capital increased to 11,60,85,737 equity shares
Total value of the paid-up equity capital now stands at Rs 1,16,08,57,370
Clerical error corrected to confirm the face value of equity shares as Rs 10.00 each
💼 Action for Investors
Investors should note the expansion in the equity base and monitor the company's deployment of the raised funds for growth. The successful completion of the rights issue at Rs 99 suggests reasonable market appetite for the company's equity.
Stallion India Allots 3.67 Crore Equity Shares via Rights Issue at Rs 99 Per Share
Stallion India Fluorochemicals has successfully completed the allotment of 3,67,60,483 equity shares following its Rights Issue. The shares were issued at a price of Rs 99 per share (including premium) in a ratio of 19:41 to eligible shareholders. This allotment has significantly expanded the company's paid-up equity capital to 11,60,85,737 shares. The completion of this exercise marks a major capital infusion for the company's balance sheet.
Key Highlights
Allotment of 3,67,60,483 fully paid-up equity shares with a face value of Rs 10 each
Issue price set at Rs 99 per equity share, including the share premium
Rights entitlement ratio maintained at 19 shares for every 41 shares held as of the record date
Total paid-up equity share capital increased to Rs 116.09 crore post-allotment
Lapsed rights entitlements have been extinguished and the specific ISIN deactivated
💼 Action for Investors
Investors should note the equity dilution resulting from the increased share base and monitor the company's upcoming quarterly results for the impact on Earnings Per Share (EPS). The successful fundraising provides capital for growth but requires efficient deployment to maintain return on equity.
Stallion India Fluorochemicals to Raise ₹363.93 Cr via Rights Issue at ₹99 per Share
Stallion India Fluorochemicals has finalized the Letter of Offer for a Rights Issue worth approximately ₹363.93 crores. The company plans to issue up to 3.67 crore equity shares at a price of ₹99 per share, which includes a premium of ₹89. Eligible shareholders as of the record date, February 11, 2026, can participate in a ratio of 19 rights shares for every 41 shares held. The issue is scheduled to open on February 20, 2026, and will close on February 27, 2026.
Key Highlights
Total issue size of up to 3,67,60,483 equity shares aggregating to ₹363.93 crores
Issue price fixed at ₹99 per share, which is 9.9 times the face value of ₹10
Rights entitlement ratio set at 19:41 for shareholders as of the February 11, 2026 record date
Issue period runs from February 20 to February 27, 2026, with market renunciation ending February 23
Expected listing date for the new rights equity shares is March 5, 2026
💼 Action for Investors
Eligible shareholders should compare the ₹99 issue price with the current market price to determine if exercising rights is beneficial. Those not intending to subscribe should sell their rights entitlements (REs) by February 23 to avoid total value loss from dilution.
Stallion India Fluorochemicals Announces Rights Issue Schedule; Opens Feb 20, 2026
Stallion India Fluorochemicals has finalized the timeline for its Rights Issue following a board meeting on February 12, 2026. The issue is scheduled to open for subscription on February 20, 2026, and will close on February 27, 2026. The record date for determining eligible shareholders was February 11, 2026. The company has secured a specific ISIN (INE0RYC20010) for the credit and trading of Rights Entitlements.
Key Highlights
Rights Issue opening date set for February 20, 2026, and closing on February 27, 2026
Record date for eligibility was Wednesday, February 11, 2026
Last date for On-Market Renunciation of Rights Entitlements is February 23, 2026
ISIN for Rights Entitlement (RE) is INE0RYC20010
Bigshare Services Private Limited appointed as the Registrar to the Issue
💼 Action for Investors
Eligible shareholders should monitor their demat accounts for Rights Entitlements and decide to either subscribe to the issue or sell their entitlements by February 23 to avoid value loss. Non-shareholders can look to purchase REs on the market if they wish to participate in the capital raise.
Stallion India to Benefit from RIPS 2024 Subsidies for Bhilwara R-32 Plant
Stallion India Fluorochemicals has announced that its upcoming greenfield R-32 manufacturing facility in Bhilwara, Rajasthan, will receive significant fiscal incentives under the Rajasthan Investment Promotion Scheme (RIPS) 2024. The benefits include capital subsidies, 75% SGST exemptions, and 100% electricity duty exemption for seven years, which are expected to significantly enhance project viability and cash flows. Additionally, the company has signed an MOU for a future HFO plant that will also qualify for similar subsidies. Management has reiterated its three-year revenue CAGR guidance of 30-35% based on these expansions.
Key Highlights
Eligible for RIPS 2024 incentives including capital subsidies and 75% SGST exemptions for the Bhilwara plant.
100% electricity duty exemption for 7 years and 75% stamp duty exemption/25% reimbursement.
Reimbursement of 50% of employer’s EPF and ESI contributions for 7 years for state-domiciled employees.
Management maintains a confident three-year revenue CAGR guidance of 30-35%.
Future HFO plant under MOU with Rajasthan government will also receive similar fiscal benefits.
💼 Action for Investors
Investors should view this as a positive development that will lower the cost of capital and improve the internal rate of return (IRR) for new projects. Monitor the commencement date of the Bhilwara plant as the 10-year incentive period begins from the start of commercial production.
Stallion India Signs ₹200 Cr MoU with Rajasthan Govt for HFO Manufacturing Plant
Stallion India Fluorochemicals has signed a Memorandum of Understanding (MoU) with the Government of Rajasthan to invest approximately ₹200 crore in a new Hydrofluoroolefin (HFO) manufacturing facility in Bhilwara. This expansion is part of a phased growth strategy, following the R32 project which is slated for commissioning by October 2026. The company aims to start work on the HFO plant in 2027, focusing on sustainable, low-global-warming-potential refrigerants. Management has provided a strong growth guidance, targeting a revenue CAGR of 30-35% over the next three years.
Key Highlights
Proposed investment of ₹200 crore for a new HFO manufacturing facility in Bhilwara, Rajasthan
Targeting a revenue CAGR of 30-35% over the next three financial years
R32 project on track for commissioning by October 2026, with HFO plant work starting in 2027
Strategic shift towards advanced HFO refrigerants to ensure long-term competitiveness and sustainability
Expansion aligns with India's self-reliance goals in the specialty and fluorochemicals sector
💼 Action for Investors
Investors should view this as a significant long-term growth driver that strengthens the company's position in the high-margin sustainable chemicals market. Monitor the successful commissioning of the R32 project in late 2026 as a key milestone before the HFO capex begins.
Stallion India Reports 72.8% PAT Growth in 9M FY26; Reaffirms FY26 Revenue Guidance of INR 430 Cr
Stallion India Fluorochemicals delivered a robust 9M FY26 performance with revenue growing 41.7% YoY to INR 321.18 crore and PAT surging 72.8% to INR 32.9 crore. The management has reaffirmed its full-year FY26 guidance of INR 430 crore revenue and INR 40 crore PAT, targeting a 30-35% CAGR over the next three years. While the Bhilwara R-32 plant is on track for August 2026, the Mambattu and Khalapur facilities have been re-engineered for higher capacity and are expected to start by Q4 FY26. Strategic tie-ups with SYS Advanced (Portugal) and Sharjah Oxygen (Dubai) are set to strengthen the company's position in the high-margin helium and semiconductor gas markets.
Key Highlights
9M FY26 PAT surged 72.8% YoY to INR 32.9 crore, while revenue reached INR 321.18 crore.
Management reaffirmed FY26 guidance of INR 430 crore revenue and INR 40 crore PAT with 30-35% CAGR target.
Environmental clearance received for 10,000 MTPA R-32 manufacturing facility at Bhilwara, Rajasthan.
Strategic technology tie-up with SYS Advanced (Portugal) and sourcing partnership with Sharjah Oxygen (Dubai) for helium.
Promoter sold 2% stake to provide interest-free funds for the R-32 plant after a planned preferential issue became unviable.
💼 Action for Investors
Investors should focus on the timely commissioning of the Bhilwara R-32 plant in August 2026, which is critical for backward integration and margin expansion. The strong earnings momentum and clear growth guidance make this a positive outlook for long-term holders.
Stallion India Sets Feb 11 as Record Date for 19:41 Rights Issue
Stallion India Fluorochemicals Limited has officially fixed February 11, 2026, as the record date for its upcoming rights issue. The company will offer 19 new equity shares for every 41 existing shares held by eligible shareholders. This corporate action is intended to raise capital from existing investors to support the company's financial objectives. Shareholders must hold the stock before the record date to be eligible for the rights entitlement.
Key Highlights
Record date for the rights issue is fixed as Wednesday, February 11, 2026
Rights entitlement ratio is set at 19 equity shares for every 41 shares held
The issuance is being conducted under Regulation 42 of SEBI LODR Regulations
The move aims to raise equity capital from the existing shareholder base
💼 Action for Investors
Investors should evaluate the rights issue price once disclosed against the current market price to decide on subscription. Existing shareholders need to hold the stock by the ex-date to receive rights entitlements.
Stallion India to Raise Rs 363.93 Cr via 19:41 Rights Issue at Rs 99 Per Share
Stallion India Fluorochemicals has approved a Rights Issue to raise approximately Rs 363.93 crores by issuing 3.67 crore equity shares. The issue price is fixed at Rs 99 per share, which includes a premium of Rs 89 over the face value of Rs 10. The company has established a rights entitlement ratio of 19 shares for every 41 shares held as of the record date, February 11, 2026. Upon full subscription, the total outstanding equity base will expand from 7.93 crore to 11.61 crore shares.
Key Highlights
Total issue size of Rs 363.93 crores involving 3,67,60,483 equity shares.
Rights entitlement ratio fixed at 19:41 (19 shares for every 41 held).
Issue price set at Rs 99 per share with full payment due on application.
Record date for eligibility is Wednesday, February 11, 2026.
Post-issue equity capital to increase by approximately 46% to 11.61 crore shares.
💼 Action for Investors
Investors should compare the current market price with the issue price of Rs 99 to assess the attractiveness of the offer. Existing shareholders must hold the stock by the Feb 11 record date to receive rights entitlements.
Stallion India to Expand with 10,000 MT R-32 Plant; Targets 3-4% Margin Boost
Stallion India Fluorochemicals is scaling its operations from 4 to 6 facilities, including a new 10,000 MT R-32 plant in Bhilwara and a 7,200 MTPA facility in Andhra Pradesh. The company is diversifying into specialty semiconductor gases and liquid helium with a 1,200 MTPA capacity investment. These initiatives, including backward integration, are expected to enhance profit margins by 3-4%. The company currently maintains a 10% market share in India and serves over 200 customers across 15 industries.
Key Highlights
Received Environmental Clearance for a 10,000 MT R-32 manufacturing facility in Bhilwara, Rajasthan.
Expanding footprint to 6 facilities with a new 7,200 MTPA plant in Andhra Pradesh expected by Q4 FY25-26.
Investing in 1,200 MTPA liquid helium capacity to serve the high-growth semiconductor and electronics industries.
Management projects that strategic backward and forward integration will improve profit margins by 3-4%.
Currently holds approximately 10% market share in India's refrigerant and industrial gas sector with 200+ customers.
💼 Action for Investors
Investors should monitor the timely commissioning of the Bhilwara and Mambattu facilities, as these are the primary catalysts for the projected margin expansion and market share growth. The entry into semiconductor gases provides a high-tech growth lever that warrants long-term attention.
Stallion India Clarifies Q3 FY26 Results; 9M PAT Surges 72.8% to ₹32.9 Crore
Stallion India Fluorochemicals issued a clarification and apology regarding inconsistent market communications for its Q3 and 9M FY26 results due to an IR-level lapse. For the nine-month period ending December 2025, the company reported a strong 41.69% revenue growth to ₹321.18 crore and a 72.81% jump in PAT to ₹32.91 crore. While Q3 EBITDA saw a slight dip of 5.21% YoY, the overall 9M performance remains robust with EBITDA growing 48.57%. The management reaffirmed its FY26 guidance of ₹430 crore revenue and ₹40 crore PAT, targeting a 30-35% CAGR over the next three years.
Key Highlights
9M FY26 Revenue grew 41.69% YoY to ₹32,118.21 Lakhs, while PAT surged 72.81% to ₹3,290.68 Lakhs.
Q3 FY26 Revenue increased 23.17% YoY to ₹10,487.90 Lakhs, though EBITDA declined 5.21% to ₹1,356.20 Lakhs.
Management maintained FY26 guidance of ₹43,000 Lakhs Revenue and ₹4,000 Lakhs PAT.
The company is expanding into semiconductor gases, liquid helium processing, and R-32 manufacturing.
Clarification was issued to address an 'inadvertent communication lapse' at the Investor Relations level.
💼 Action for Investors
Investors should focus on the strong 9M growth trajectory and the management's ambitious 3-year CAGR targets while monitoring for improved internal communication controls. The underlying business performance remains robust despite the reporting inconsistency.
Stallion India Receives In-Principle Approval for Rs 364 Crore Rights Issue
Stallion India Fluorochemicals Limited has secured in-principle approval from both NSE and BSE for a proposed rights issue. The company intends to raise up to Rs 364 crore through the issuance of equity shares to its existing eligible shareholders. While the specific issue price, rights ratio, and record date are yet to be finalized, this approval is a critical step in the company's capital-raising process. The final terms of the issue will be disclosed at least three working days prior to the record date.
Key Highlights
Received in-principle approval from NSE and BSE on January 30, 2026, for the proposed rights issue.
The total fundraise amount is capped at an aggregate of Rs 364 Crores.
The issue involves equity shares with a face value of Rs 10 each, with the premium to be decided later.
The company is required to announce the rights price and ratio at least 3 working days before the record date.
The approval is subject to fulfilling standard SEBI and exchange listing conditions.
💼 Action for Investors
Investors should monitor future announcements for the specific rights ratio and issue price to evaluate the potential dilution and the discount offered. Existing shareholders should prepare to decide whether to subscribe to the issue or renounce their rights once the record date is announced.
Stallion India Q3 & 9M FY26: 9M PAT Surges 72.8% YoY to ₹32.9 Crore
Stallion India Fluorochemicals reported robust 9M FY26 results with revenue rising 41.7% YoY to ₹321.2 crore and PAT jumping 72.8% to ₹32.9 crore. The company has already achieved approximately 82% of its full-year PAT guidance of ₹40 crore within the first nine months. Strategic expansions into semiconductor gases and the upcoming R-32 manufacturing facility are expected to boost margins by 3-4%. Management remains confident in sustaining a 30-35% CAGR over the next three years.
Key Highlights
9M FY26 PAT surged 72.81% YoY to ₹3,290.68 Lakhs from ₹1,904.25 Lakhs.
Total Revenue for 9M FY26 grew 41.69% YoY to ₹32,118.21 Lakhs.
Received Environmental Clearance for a 10,000 MT R-32 facility, targeting August 2026 commissioning.
Management maintains FY26 guidance of ₹430 Cr revenue and ₹40 Cr PAT, with potential to surpass it.
Expanding into high-growth sectors like semiconductor gases and 1,200 MT liquid helium processing.
💼 Action for Investors
The company is demonstrating high growth and is likely to exceed its annual guidance, making it a strong candidate for growth-oriented portfolios. Investors should monitor the timely execution of the Bhilwara and Khalapur expansion projects as key margin drivers.
Stallion India Q3 & 9M FY26 Results: 9M PAT Surges 72.8% YoY to ₹32.9 Crore
Stallion India Fluorochemicals reported a robust performance for 9M FY26, with revenue growing 41.7% to ₹321.18 crore and PAT surging 72.8% to ₹32.91 crore. The company is on track to meet its full-year revenue guidance of ₹430 crore and PAT of ₹40 crore, having already achieved over 80% of the PAT target. Management highlighted strategic expansions in HFO/HFC blending and semiconductor gases, alongside receiving environmental clearance for a new R-32 manufacturing facility. These initiatives are projected to enhance profit margins by 3-4% and support a 30-35% CAGR over the next three years.
Key Highlights
9M FY26 PAT grew by 72.81% YoY to ₹3,290.68 Lakhs
9M FY26 Revenue increased by 41.69% YoY to ₹32,118.21 Lakhs
EBITDA for 9M FY26 rose 48.57% YoY to ₹4,369.91 Lakhs
Management maintains FY26 guidance of ₹430 Cr revenue and ₹40 Cr PAT
Environmental Clearance received for 10,000 MT R-32 facility, expected to commission by August 2026
💼 Action for Investors
Investors should view this as a strong growth story given the significant margin expansion and clear roadmap in high-growth sectors like semiconductors. Monitor the timely commissioning of the Bhilwara facility and the achievement of the full-year PAT guidance.
Stallion India Fluorochemicals Q3 PAT at ₹11.13 Cr; 9M FY26 Profit Reaches ₹32.44 Cr
Stallion India Fluorochemicals reported a marginal sequential decline in revenue to ₹104.65 crore for the quarter ended December 31, 2025, compared to ₹105.56 crore in the previous quarter. Net profit for Q3 FY26 stood at ₹11.13 crore, reflecting a slight dip from ₹12.00 crore in Q2 FY26. For the nine-month period, the company achieved a total profit of ₹32.44 crore. The company is actively deploying IPO proceeds, having already utilized ₹95 crore for working capital, while capital expenditure for its new specialty gas facilities is in the early stages.
Key Highlights
Revenue from operations for Q3 FY26 stood at ₹104.65 crore, a marginal 0.8% decrease quarter-on-quarter.
Net Profit for the quarter was ₹11.13 crore, with an Earnings Per Share (EPS) of ₹1.48.
For the nine months ended December 2025, the company recorded a total income of ₹314.11 crore and PAT of ₹32.44 crore.
Out of ₹148.74 crore net IPO proceeds, ₹95 crore has been fully utilized for incremental working capital requirements.
Capital expenditure for the Semiconductor and Specialty Gas facility in Khalapur and the Refrigerant facility in Mambattu is ongoing, with significant funds still held in fixed deposits.
💼 Action for Investors
Investors should monitor the execution timelines of the Khalapur and Mambattu facilities, as these specialty gas projects are critical for long-term margin expansion. The current performance shows stability, but growth will depend on the successful commissioning of these new capacities.
Stallion India Partners with SYS ADVANCE for Helium Systems; Targets 30-35% Revenue CAGR
Stallion India Fluorochemicals has entered a strategic technology tie-up with Portugal-based SYS ADVANCE to develop Helium Recovery and Liquefaction systems. This partnership provides Stallion with access to technology qualified by European Space Agencies, targeting high-barrier sectors like space and defense. The company is currently participating in a large ISRO tender, which could establish it as a premier technology provider in this niche segment. Management has reiterated a strong 3-year revenue CAGR guidance of 30-35% following this expansion.
Key Highlights
Strategic MoU with SYS ADVANCE for European Space Agency-qualified Helium recovery technology.
Management maintains a 3-year revenue CAGR guidance of 30-35% driven by advanced gas technologies.
Company has participated in a large tender floated by ISRO for Helium Recovery and Liquefaction.
SYS ADVANCE brings global expertise with over 4,000 PSA systems operating in 40+ countries.
Expansion supports Stallion's positioning in high-purity industrial and semiconductor gases.
💼 Action for Investors
Investors should monitor the outcome of the ISRO tender as a successful bid would be a major valuation catalyst. The aggressive 30-35% CAGR guidance suggests significant growth potential in the specialized industrial gas market.
Stallion India Fluorochemicals Files DLOF for ₹364 Crore Rights Issue
Stallion India Fluorochemicals Limited has submitted its Draft Letter of Offer (DLOF) for a proposed Rights Issue to raise up to ₹364.00 crores. The issue will involve the offering of fully paid-up equity shares with a face value of ₹10 each to existing eligible shareholders. This capital raising initiative follows the company's recent listing on the main board of BSE and NSE in January 2025. Specific details regarding the issue price, entitlement ratio, and record date are currently pending and will be finalized in the Letter of Offer.
Key Highlights
Proposed Rights Issue size of up to ₹364.00 crores for existing shareholders.
Draft Letter of Offer (DLOF) submitted to BSE and NSE on January 24, 2026.
Equity shares carry a face value of ₹10.00 each; issue price and ratio to be determined.
The company was recently listed on the main board segments on January 23, 2025.
Bigshare Services Private Limited has been appointed as the Registrar to the Issue.
💼 Action for Investors
Investors should wait for the announcement of the Rights Issue price and entitlement ratio to evaluate the potential dilution and valuation. Existing shareholders should monitor for the record date to determine eligibility for participation or renunciation of rights.
Stallion India Fluorochemicals to Raise Up to Rs 364 Crore via Rights Issue
Stallion India Fluorochemicals Limited has approved a significant fundraise of up to Rs 364 crore through a rights issue of equity shares. The board has formed a Rights Issue Committee to finalize critical details including the issue price, entitlement ratio, and the record date. Currently, the company has 7,93,25,254 outstanding equity shares. This capital infusion is expected to support the company's financial structure or growth initiatives, though specific utilization details will be provided in the Letter of Offer.
Key Highlights
Board approved a Rights Issue aggregating up to Rs 364.00 Crores.
Current outstanding equity shares stand at 7,93,25,254 shares with a face value of Rs 10 each.
A Rights Issue Committee has been formed to determine the final price, ratio, and timing.
The full issue price will be payable by eligible shareholders at the time of application.
💼 Action for Investors
Investors should monitor for the announcement of the record date and issue price to evaluate the discount and potential dilution of their holdings.
Stallion India Allotted 28,650 Sqm Land for R-32 Plant; Targets ₹500 Cr Revenue
Stallion India Fluorochemicals has secured a 28,650 sq. meter industrial plot from RIICO in Rajasthan to support its R-32 manufacturing facility. The plant, which recently received environmental clearance, will have a 10,000 MTPA capacity for R-32 and 7,500 MTPA for blended refrigerants. Management expects the facility to generate ₹500 crore in annual revenue with PAT margins of 22-24% once commissioned in August 2026. This expansion underpins the company's aggressive 3-year revenue CAGR guidance of 30-35%.
Key Highlights
Allotment of 28,650 sq. meters of land in Rajasthan for R-32 manufacturing expansion
Planned capacity of 10,000 MTPA for R-32 and 7,500 MTPA for blended refrigerants
Projected annual revenue of ₹500 crore with PAT margins between 22-24%
Commercial commissioning targeted for August 2026 with construction already started
Management maintains a 3-year revenue CAGR guidance of 30-35%
💼 Action for Investors
Investors should track the project's execution timeline as the August 2026 commissioning is a key catalyst for revenue growth. The high projected PAT margins suggest significant potential for earnings per share (EPS) accretion.
Stallion India Allotted 28,650 Sq. Mtr. Industrial Plot in Rajasthan for Expansion
Stallion India Fluorochemicals Limited has received an allotment letter from RIICO for an industrial plot in Ukhaliya, Rajasthan. The plot, measuring approximately 28,650 square meters, was secured under the Direct Allotment Policy-2025. This land acquisition is strategically intended to support the expansion and operational requirements of the company's existing R-32 Manufacturing Plant. This move signals a clear commitment to long-term growth and capacity building in the fluorochemicals sector.
Key Highlights
Allotment of Plot No. SP3-11 measuring approximately 28,650 square meters in Ukhaliya, Rajasthan.
Plot allotted by RIICO under the 'Direct Allotment Policy-2025' for industrial use.
Expansion is designed to support the existing R-32 Manufacturing Plant located at the adjacent Plot No. SP3-10.
Strategic acquisition aimed at scaling production capacity and enhancing operational efficiency.
💼 Action for Investors
Investors should view this as a positive growth indicator; monitor future announcements regarding the capital expenditure (CAPEX) and commissioning timeline for the new facility.